Select the Abstracts by Number

Click    to view the poster

442   Biochemical Evidence of Cross-Resistance to Stavudine (d4T) Triphosphate in Purified HIV-1 Reverse Transcriptase (RT) Derived from a Zidovudine (AZT)- Resistant Isolate.

443   Comparison of Evolutionary Distances between DNA Polymerase and RNase H Domains of HIV-1 Reverse Transcriptase (RT) in Patients with and without Exposure to Nucleoside Analogue Therapy.

444   Virologic Suppression from Different Thymidine Analogue (TA)-Containing HAART Regimen Sequencing Strategies: VIRA3001.

445   Viral Resistance Results from the International, Multicenter, Randomized, Placebo-Controlled, 48-Week Study of Hydroxyurea (HU) or Placebo Combined with Efavirenz (EFV), Didanosine (ddl) and Stavudine (d4T) in Treatment-Naive and - Experienced Patients.

446   Drug-Selected HIV-1 Mutations Can Differ in Cervico- Vaginal and Blood Plasma RNA.

447   3TC-Related Mutations and Response to Therapy.

448   Time to Appearance of NRTI-Associated Mutations and Response to Subsequent Therapy for Patients on Failing ABC/COM.

449   Resistance Profile and Cross-Resistance to HIV-1 among 104 Patients Failing a Non-Nucleoside Reverse Transcriptase Inhibitor- Containing Regimen.

450   Presence of Thymidine- Associated Mutations and Response to d4T, Abacavir and ddI in the Control Arm of the Narval ANRS 088 Trial.

451   Polymorphisms in the HIV-1 Protease as Predictors of Early Virological Failures in a Cohort of Antiretroviral-Naive Patients Initiating a PI- Containing Regimen (APROCO- ANRS EPI11 Study).

452   Patterns of Protease Inhibitor Cross-Resistance in Viral Isolates with Reduced Susceptibility to ABT-378.

453   Absence of Resistance to Kaletra (ABT-378/r) Observed through 48 Weeks of Therapy in Antiretroviral-Naive Subjects.

454   Decreased Susceptibility, Not Hypersensitivity, to Non- Nucleoside Reverse Transcriptase Inhibitors (NNRTI) in Patients Treated with Nucleoside Analogues (NRTI).

455   Worldwide Variation in Antiretroviral Phenotypic Susceptibility in Untreated Individuals.

456   Patterns of Drug Resistance: Do We Need To Adjust Treatment to Clade?

457   Genotypic Diversity of HIV-1 in Recently Infected Patients from Abidjan (Cote d Ivoire) and Relationship to Drug Resistance.

458   Performance of the VIRCO Drug Resistance Assays Testing HIV-1 Non-B Subtypes.

459   Amino Acid Mutation Patterns in Reverse Transcriptase and Protease Sequences from Subtype B, Non- B and Recombinant Forms of HIV from Infected Individuals in Spain (Galicia).

460   Drug-Selected and Non- Clade B pol Genotypes in Chronically HIV-1-Infected Antiretroviral-Naive Adults in Boston.

461   Diversity between HIV-1 and HIV-2 Protease Sequences: Implications for Evolution of Drug Resistance in HIV-2.

462   Distinctive Patterns of HIV-1 PR-RT Resistance Mutations in HIV-1 Subtypes Are Independent of Treatment Length.

463   HIV-1 Reverse Transcriptase (RT) M184V/I Improves the Rate of Suppression of Viral Replication by Salvage Therapy.

464   Opposing Effects of AZT Resistance and Foscarnet Resistance Mutations on Nucleotide-Dependent Removal of AZTMP from Blocked Primer/ Templates by HIV-1 Reverse Transcriptase Suggests Potential Benefits of Combination Therapy with AZT and Foscarnet.

465   Plasma Trough Levels Correlate with Distinct Genetic Mechanisms During the Development of Amprenavir Resistance.

466   Molecular Mechanism of I50V HIV-1 Protease Resistance and Cross-Resistance to Protease Inhibitors.

467   Genotypic Mutations in the Protease (Pr) and Reverse Transcriptase (RT) Genes Associated with Antiretroviral Resistance to Combination Therapy with Ritonavir/AZT/3TC: A Virological Sub-Study of PACTG 345.

468   Analysis of HIV-1 Drug Resistance in a Randomized, Controlled Trial of a Combination of Nucleoside Analog Reverse Transcriptase (RT) Inhibitors Plus Nevirapine (NVP), Nelfinavir (NFV), or Ritonavir (RTV) in Stable Antiretroviral Therapy- Experienced HIV-Infected Children.

469    Resistance Profiles in HIV-1-Infected Children: A Call for Resistance Testing.

470   Genotypic Resistance Analysis in French Women Participating in PACTG316/ANRS 083.

471   Why Does Stavudine Select Zidovudine Resistance Mutations In Vivo?

472   In VitroSelection and Characterisation of HIV-1 Resistance to BCH-10618.

473   Virus Sensitivity to T-20 and T-1249 Is Independent of Coreceptor Usage.

474   Correlation of gp41 Binding and Antiviral Potencies of the T-20 Fusion Inhibitor Using Clinical Trial Isolate-Derived Sequences.

475   Sensitivity of HIV-1 to the Fusion Inhibitors T-20 and T-649 Is Modulated by Coreceptor Specificity and Involves Distinct Regions of gp41.